Jose Alfon
R&D Department, Parc Tecnològic Del Vallès, Cerdanyola Del Vallès
Barcelona, CT, Spain
Barcelona, CT, Spain
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 12 publications
Corrigendum: Anticancer effects of ABTL0812, a clinical stage drug inducer of autophagy-mediated cancer cell death, in glioblastoma models.
Journal: Frontiers in oncology
Published: December 03, 2024
ENDOLUNG trial, part II. A phase II study of the Akt/mTOR inhibitor and autophagy inducer ibrilatazar (ABTL0812) in combination with paclitaxel/carboplatin in patients with squamous non-small cell lung cancer.
Journal: Lung cancer (Amsterdam, Netherlands)
Published: November 06, 2024
Anticancer effects of ABTL0812, a clinical stage drug inducer of autophagy-mediated cancer cell death, in glioblastoma models.
Journal: Frontiers in oncology
Published: May 13, 2022
ABTL0812 enhances antitumor effect of paclitaxel and reverts chemoresistance in triple-negative breast cancer models.
Journal: Cancer communications (London, England)
Published: January 31, 2022
A first-in-human phase I/Ib dose-escalation clinical trial of the autophagy inducer ABTL0812 in patients with advanced solid tumours.
Journal: European journal of cancer (Oxford, England : 1990)
Published: September 10, 2020
The antitumour drug ABTL0812 impairs neuroblastoma growth through endoplasmic reticulum stress-mediated autophagy and apoptosis.
Journal: Cell death & disease
Published: June 12, 2020
The anti-cancer drug ABTL0812 induces ER stress-mediated cytotoxic autophagy by increasing dihydroceramide levels in cancer cells.
Journal: Autophagy
Published: May 14, 2020
The novel proautophagy anticancer drug ABTL0812 potentiates chemotherapy in adenocarcinoma and squamous nonsmall cell lung cancer.
Journal: International journal of cancer
Published: May 14, 2019
Therapeutic potential of the new TRIB3-mediated cell autophagy anticancer drug ABTL0812 in endometrial cancer.
Journal: Gynecologic oncology
Published: January 07, 2019
The New Antitumor Drug ABTL0812 Inhibits the Akt/mTORC1 Axis by Upregulating Tribbles-3 Pseudokinase.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: July 30, 2015
Showing 1-12 of 12
Last Updated: 09/26/2026